A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor

• Published in: Journal of psychopharmacology (Oxford) 2018-12, Vol.32 (12), p.1351-1361
• Main Authors: Carter, Lawrence P, Henningfield, Jack E, Wang, Y Grace, Lu, Yuan, Kelsh, Debra, Vince, Bradley, Sellers, Edward
• Format: Article
• Language: English
• Subjects: Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - adverse effects; Adrenergic Uptake Inhibitors - pharmacology; Adult; Adults; Antidepressants; Anxiety; Carbamates - administration & dosage; Carbamates - adverse effects; Carbamates - pharmacology; Catecholamines; Cross-Over Studies; Crossovers; Dopamine; Dopamine Uptake Inhibitors - administration & dosage; Dopamine Uptake Inhibitors - adverse effects; Dopamine Uptake Inhibitors - pharmacology; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Drug abuse; Drug dosages; Female; Humans; Insomnia; Liability; Male; Mood; Norepinephrine; Original Papers; Phentermine - administration & dosage; Phentermine - adverse effects; Phentermine - pharmacology; Phenylalanine - analogs & derivatives; Randomization; Recreational use; Sleep disorders; Stimulants; Substance-Related Disorders - psychology; Young Adult
• ISSN: 0269-8811; 1461-7285
• DOI: 10.1177/0269881118796814

Background: This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. Methods: Adults with a recent history of recreational polydrug use, including stimulants, and who met criteria in a Qualification Phase were randomized to one of six sequences in a Test Phase. Each Test Phase sequence included a single administration of placebo, solriamfetol (300, 600, and 1200 mg), and phentermine (45 and 90 mg), with a two-day washout between periods. The primary endpoint was peak rating (Emax) of Liking at the Moment across the first 12 h on a liking/disliking visual analog scale; key secondary endpoints were Next Day Overall Drug Liking, how much the participant would like to Take the Drug Again, and positive and negative subjective effects. Safety was also assessed throughout the study. Results: Of 43 participants (74.4% male; mean age 29.3 years), 37 completed the study. Peak Emax Liking at the Moment for all solriamfetol doses was significantly greater than placebo and significantly less than phentermine 90 mg (p < 0.05). Overall Next Day Drug Liking was greater than placebo for solriamfetol 300 mg and phentermine 45 and 90 mg (p < 0.05). Willingness to Take the Drug Again was significantly greater than placebo and significantly less than both doses of phentermine for all doses of solriamfetol (p < 0.05). Ratings of negative subjective effects (bad effects, disliking, anxiety, agitation) were higher with solriamfetol 600 and 1200 mg relative to phentermine. The most common treatment-emergent adverse events with solriamfetol were hypervigilance, elevated mood, dry mouth, hyperhidrosis, and insomnia. Conclusion: Solriamfetol appears to have abuse potential similar to or lower than phentermine.